US2014038210A1PendingUtilityA1
ANTI-HUMAN IgG1 ANTIBODY
Est. expiryAug 17, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Ulrich EssigStefan KlostermannFrank KowalewskyKay-Gunnar StubenrauchRudolf VogelUwe Wessels
C07K 2317/33G01N 33/68C07K 16/4283C12N 5/163C07K 16/42C07K 2317/92C12N 5/12G01N 33/6854C07K 2317/14G01N 33/686C07K 2317/54C07K 2317/30C07K 16/18C07K 16/4241
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A monoclonal antibody characterized in that the antibody specifically binds to an antibody of human IgG1 class and does not specifically bind to the immunoglobulin of rhesus-monkey, marmoset monkey, baboon monkey and cynomolgus monkey.
2 . The antibody according to claim 1 , characterized in that the antibody binds to an antibody of human IgG1 class with a kappa light chain.
3 . The antibody according to any one of the preceding claims, characterized in that the antibody does not bind to an antibody of human IgG1 class with a lambda light chain.
4 . The antibody according to any one of claims 1 and 2 , characterized in that the antibody binds to an antibody of human IgG1 class with a lambda light chain.
5 . The antibody according to any one of claims 1 , 2 and 4 , characterized in that the antibody does not bind to an antibody of human IgG2 class.
6 . The antibody according to any one of claims 1 , 2 and 4 to 5 , characterized in that the antibody does not bind to an antibody of human IgG4 class.
7 . The antibody according to any one of claims 1 , 2 and 4 to 6 , characterized in that the antibody binds to the Fab of an antibody of human IgG1 class with a lambda light chain.
8 . The antibody according to any one of the preceding claims, characterized in that the antibody binds to the Fab of an antibody of human IgG1 class with a kappa light chain.
9 . The antibody according to any one of the preceding claims, characterized in the antibody does not bind to an antibody of human IgG3 class.
10 . The antibody according to any one of the preceding claims, characterized in that the antibody is a non-human animal derived antibody.
11 . The antibody according to any one of the preceding claims, characterized in that the antibody is specifically binding to the heavy chain constant region 1 of an antibody of human IgG1 class.
12 . The monoclonal antibody obtained from the cell line DSM ACC3006.
13 . A monoclonal antibody characterized in that the antibody is specifically binding to the same or an overlapping epitope as the antibody produced by the cell line DSM ACC3006, or DSM ACC3007.
14 . The cell line DSM ACC3006.
15 . The monoclonal antibody obtained from the cell line DSM ACC3007.
16 . The monoclonal antibody obtained from the cell line DSM ACC3008.
17 . A monoclonal antibody characterized in that the antibody is specifically binding to the same or an overlapping epitope as the antibody produced by the cell line DSM ACC3008.
18 . The cell line DSM ACC3007.
19 . The cell line DSM ACC3008.
20 . The monoclonal antibody obtained from the cell line DSM ACC3076.
21 . A monoclonal antibody characterized in that the antibody is specifically binding to the same or an overlapping epitope as the antibody produced by the cell line DSM ACC3076.
22 . The cell line DSM ACC3076.
23 . The use of an antibody according to any one of claims 1 to 13 and 15 to 17 and 20 to 21 in an immunoassay.
24 . Kit comprising
a) an antibody obtained from cell line DSM ACC3006, or DSM ACC 3007, or DSM ACC3008, or DSM ACC3076 as capture reagent, b) an antibody obtained from cell line DSM ACC3006, or DSM ACC 3007, or DSM ACC3008, or DSM ACC3076 as detection reagent.
25 . A method for detecting a therapeutic antibody of human IgG1 class in a sample obtained from an experimental animal comprising the steps of
a) incubating a sample to be analyzed with a monoclonal antibody according to any one of claims 1 to 13 and 15 to 17 and 20 to 21 , b) optionally incubating the sample with a reagent for the selective detection of total, active, ADA-bound, or antigen-bound therapeutic antibody, and c) correlating the complex formed in (a) or (b) to the presence of the therapeutic antibody and thereby detecting the therapeutic antibody.
26 . A Method for determining a therapeutic antibody of human IgG1 class in a sample obtained from an experimental animal using an immunoassay comprising a capture antibody and a tracer antibody, characterized in that the capture antibody and/or the tracer antibody are both independently selected from an antibody according to any one of claims 1 to 13 and 15 to 17 and 20 to 21 .
27 . The method according to any one of claims 25 to 26 , characterized in that the therapeutic antibody is a Fab.
28 . The antibody according to claims 1 to 13 and 15 to 17 and 20 to 21 and the method according to any one of claims 25 to 27 , characterized in that the experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof.
29 . The use of an antibody which is specifically binding to a therapeutic antibody of human IgG1 class and not specifically binding to the immunoglobulin of an experimental animal for determining the concentration of total, active, ADA-bound, or antigen-bound therapeutic antibody in a sample obtained from an experimental animal whereby the antibody is an antibody according to any one of claims 1 to 13 and 15 to 17 and 20 to 21 .
30 . An antibody composition, characterized in comprising a mixture of the antibodies produced by the cell line DSM ACC3006, and/or the cell line DSM ACC3007, and/or the cell line DSM ACC3008, and/or the cell line DSM ACC3076, and/or the cell line DSM ACC2708.
31 . The use of an antibody composition according to claim 30 in a method according to any one of claims 25 to 27 .Join the waitlist — get patent alerts
Track US2014038210A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.